MBX Biosciences is a biotechnology company creating therapies for rare endocrine diseases. Members of MBX's leadership team previously collaborated in the creation of highly successful endocrine drugs (Humalog®, Forteo®) and three Indiana-based companies (Marcadia, Calibrium and MB2). MBX is strengthened by world-class proprietary technology and drug candidates licensed from the DiMarchi Indiana University laboratory.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/27/20 | $34,600,000 | Series A |
Frazier Healthcare Partners Indiana Philanthropic Venture Fund Indiana Seed Fund New Enterprise Associates OrbiMed Advisors Twilight Venture Partners | undisclosed |
| 11/14/22 | $115,000,000 | Series B |
Frazier Healthcare Partners New Enterprise Associates Norwest Venture Partners OrbiMed Advisors RA Capital Management Wellington Management Company | undisclosed |
| 08/05/24 | $63,500,000 | Series C |
Deep Track Capital Driehaus Capital Management Frazier Life Sciences OrbiMed Advisors T. Rowe Price Associates Wellington Management | undisclosed |
